Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX

Kyverna Therapeutics

Kyverna Therapeutics clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
5980 Horton St, Suite 550, Emeryville, California 94608, US HQ
2018 Founded
155 Employees
Public company Type
KYTX · NYSE Ticker
Company details
Status
Public
HQ
5980 Horton St, Suite 550, Emeryville, California 94608, US
Founded
2018
Employees
155
Programs
14
Drugs
31
Patents
2
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Kyverna Therapeutics projects

14 ClinicalTrials.gov programs sponsored by Kyverna Therapeutics.

Kyverna Therapeutics has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

14 programs

Clinical programs

  1. KYV-101

    Kyverna Therapeutics

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial

  2. KYV101-006

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  3. Standard of Care Treatment

    Kyverna Therapeutics

    Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. CCM-RNT-202402

    Kyverna Therapeutics

    ANCA-IgG-positive ANCA Associated Vasculitis

    phase 2 small molecule active

    1 trial

  5. KYV-101

    Kyverna Therapeutics

    Multiple Sclerosis, Primary Progressive

    phase 2 mab active

    1 trial

  6. KYV-101

    Kyverna Therapeutics

    Systemic Sclerosis

    phase 2 mab active

    1 trial

  7. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 mab active

    2 trials

  8. KYV101

    Kyverna Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  9. KYV101-003

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

  10. KYV101-007

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  11. Standard lymphodepletion regimen

    Kyverna Therapeutics

    Stiff-Person Syndrome

    phase 2 mab active

    1 trial

  12. KYV-101

    Kyverna Therapeutics

    Idiopathic Inflammatory Myopathies

    phase 1 small molecule active

    1 trial

  13. KYV-101 (Biological) - 0.33 ×10^8 cells

    Kyverna Therapeutics

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  14. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Multiple Sclerosis

    phase 1 mab active

    1 trial

Frequently asked questions

How many clinical projects does Kyverna Therapeutics have?

14 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.